In vitro inhibitory effects of imatinib mesylate on stromal cells and hematopoietic progenitors from bone marrow
Imatinib mesylate (IM) is used to treat chronic myeloid leukemia (CML) because it selectively inhibits tyrosine kinase, which is a hallmark of CML oncogenesis. Recent studies have shown that IM inhibits the growth of several non-malignant hematopoietic and fibroblast cells from bone m...
Main Authors: | P.B. Soares, T.S. Jeremias, M. Alvarez-Silva, M.A. Licinio, M.C. Santos-Silva, C.L. Vituri |
---|---|
Format: | Article |
Language: | English |
Published: |
Associação Brasileira de Divulgação Científica
2013-01-01
|
Series: | Brazilian Journal of Medical and Biological Research |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2013000100039&lng=en&tlng=en |
Similar Items
-
by: P.B. Soares, et al.
Published: (2013-01-01) -
Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours
by: Ruth Gauden, et al.
Published: (2011-04-01) -
Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
by: Sumin Tang, et al.
Published: (2017-04-01) -
Primary Prostatic Extra-Gastrointestinal Stromal Tumor Treated with Imatinib Mesylate as Neoadjuvant and Adjuvant Therapy: A Case Report and Literature Review
by: Shen H, et al.
Published: (2019-12-01) -
Tuberculous and Non-Tuberculous Granulomatous Lymphadenitis in Patients Receiving ImatinibMesylate (Glivec) for Metastatic Gastrointestinal Stromal Tumor
by: Abbas Agaimy, et al.
Published: (2013-03-01)